Specialties

Diabetes or prediabetes may put a patient at higher risk of developing cardiovascular diseases.

The impact of impaired healing in those with diabetes mellitus (DM) contributes to their higher risk of developing periodontitis, leading to tooth loss (TL).  

All male patients with low testosterone levels are at a higher risk for cardiovascular disease, especially those with type 2 diabetes mellitus.  

Dapagliflozin (Farxiga®) has been granted U.S. Food and Drug Administration (FDA)  Breakthrough Therapy Designation (BTD) for patients with chronic kidney disease (CKD), whether or not they have type 2 diabetes. 

Should current guidelines lower the blood pressure treatment threshold for increased prevention of CVD?

Addressing the gaps in lipoprotein cholesterol (LDL-C) control and statin prescribing among patients with type 2 diabetes.

In addition to clinical trials, does data from a meta-analysis of retrospective cohort studies support the benefits of SGLT-2 inhibitors?

Despite being on first-line oral anti-diabetic drug therapy, the risk of developing CVD/CKD in patients with type 2 diabetes remains high.

Examining how curcumin and other bioactive compounds in turmeric lower blood glucose.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events.